Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) Income from Continuing Operations (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Income from Continuing Operations for 6 consecutive years, with 44076000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations fell 559.03% year-over-year to 44076000.0, compared with a TTM value of 66539000.0 through Dec 2025, down 1005.3%, and an annual FY2025 reading of 66539000.0, down 1005.3% over the prior year.
  • Income from Continuing Operations was 44076000.0 for Q4 2025 at Cytek Biosciences, down from 5478000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 9602000.0 in Q4 2024 and bottomed at 44076000.0 in Q4 2025.
  • Average Income from Continuing Operations over 5 years is 3957800.0, with a median of 1661500.0 recorded in 2021.
  • Peak annual rise in Income from Continuing Operations hit 419.14% in 2022, while the deepest fall reached 2215.69% in 2022.
  • Year by year, Income from Continuing Operations stood at 1165000.0 in 2021, then soared by 419.14% to 3718000.0 in 2022, then skyrocketed by 48.01% to 5503000.0 in 2023, then surged by 74.49% to 9602000.0 in 2024, then crashed by 559.03% to 44076000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for CTKB at 44076000.0 in Q4 2025, 5478000.0 in Q3 2025, and 5583000.0 in Q2 2025.